


**IN THE CLAIMS:**

✓  
Please amend Claims 1-7 and 13, by replacing them with the following Rewritten Claims. A copy of the Marked-up Claims is attached for the Examiner's convenience.


Rewritten Claims

1. A pharmaceutical composition comprising a compound of Formula I,



wherein

R<sup>1</sup> is selected from alkyl; aryl-loweralkyl; loweralkyl-carbonate; amino monosubstituted or disubstituted with a hydroxyloweralkyl; benzimidaz-2-yl;



A1  
 cont.

wherein  $R^4$  is phenyl optionally monosubstituted or disubstituted with a substituent selected from loweralkyl and halo; phenyl optionally monosubstituted or disubstituted with a substituent selected from amino, loweralkoxy, hydroxy and loweralkyl;  $NHCH_2CH_2OX$  wherein X represents an *in vivo* hydrolyzable ester; and  $C_2-C_4$  alkyl- $(R^5)(R^6)$  wherein one of  $R^5$  and  $R^6$  is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxy-carbonyl; and

$R^2$  and  $R^3$  are independently selected from H,  $NO_2$ , halo, di(loweralkyl)amino, loweralkyl and phenyl-S-, with the proviso that both  $R^2$  and  $R^3$  are not both hydrogen.

3. A pharmaceutical composition according to claim 2, wherein  $R^1$  is selected from aryl-loweralkyl; loweralkyl-carbonate; amino monosubstituted or disubstituted with hydroxyloweralkyl; benzimidaz-2-yl;  $NHCH_2CH_2OX$  wherein X represents an *in vivo* hydrolyzable ester; and  $C_2-C_4$  alkyl- $(R^5)(R^6)$  wherein one of  $R^5$  and  $R^6$  is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxy-carbonyl; and

R<sup>2</sup> and R<sup>3</sup> are independently selected from H, NO<sub>2</sub>, di(loweralkyl)amino, loweralkyl and phenyl-S-, with the proviso that both R<sup>2</sup> and R<sup>3</sup> are not both hydrogen.

4. A pharmaceutical composition according to claim 3, wherein R<sup>1</sup> is selected from amino monosubstituted or disubstituted with hydroxyloweralkyl; NHCH<sub>2</sub>CH<sub>2</sub>OX wherein X represents an *in vivo* hydrolyzable ester; and C<sub>2</sub>-C<sub>4</sub> alkyl-(R<sup>5</sup>)(R<sup>6</sup>) wherein one of R<sup>5</sup> and R<sup>6</sup> is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxy-carbonyl; and

A1  
cont-  
R<sup>2</sup> and R<sup>3</sup> are independently selected from H, loweralkyl and NO<sub>2</sub>, with the proviso that both R<sup>2</sup> and R<sup>3</sup> are not both hydrogen.

5. A pharmaceutical composition according to claim 1 wherein the compound of Formula I is selected from the group consisting of:

N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;

2-{2-(4-Methylphenylsulphonamido)phenyl}-6-(N,N-dimethylamino)-naphthalimide;

N-Octyl-5-nitronaphthalimide;

2-{2-(4-Methylbenzylsulphonamido)-4,5-dichlorophenyl}naphthalimide;

3-Nitro-1,8-(N-propioncarboxylate)succinamidonaphthalene;

3-Amino-7,4-bis(ethyl-1,3-dioxo)-1,2,3,4-tetrahydrobenzo[i]isoquinoline;

2-(Benzimidaz-2-yl)-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline;

~~1,3-Dioxo-2-{4,5-dimethyl-2-(4-methylphenylsulphonamido)phenyl}-  
 1,2,3,4-tetrahydrobenzo[i]isoquinoline;  
 3-Methyl-3-(1,3-dioxo-5-nitro(1H,3H)benz[de]isoquinolyl)butyric acid methylester;  
 N-(4-Ethoxyphenyl)-5-nitronaphthalimide;  
 Ethyl-5-nitro-1,3-dioxo-1H-benz[de]isoquinoline-2-3H-acetate;  
 Naphthalicacid-N,N'-diimide;  
 5-Amino-N-butyl-naphthalimide;  
 1,3-Dioxo-5-nitro-n-propylmorpholino-1,2,3,4-tetrahydrobenzo[i]isoquinoline; and  
 N-(1,3-Dioxo-6-phenylmercapto-1,2,3,4-tetrahydrobenzo[i]isoquinoline)-  
 aminoethanol.~~

6. A pharmaceutical composition according to claim 2 wherein the compound of Formula I is  
 selected from the group consisting of:

~~N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;  
 N-Octyl-5-nitronaphthalimide;  
 2-{2-(4-Methylbenz-sulphonamido)-4,5-dichlorophenyl}naphthalimide;  
 3-Nitro-1,8-(N-propioncarboxylate)succinamidonaphthalene;  
 3-Amino-7,4-bis(ethyl-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline; and  
 2-(Benzimidaz-2-yl)-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline.~~

A<sup>1</sup>  
cont- 7. A pharmaceutical composition according to claim 1 wherein the compound of Formula I is N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol or its pharmaceutically acceptable salt.

A<sup>2</sup>  
Sub B<sup>m</sup> 13. An *in vivo* hydrolyzable ester or amide of a compound selected from the group consisting of:  
N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;  
3-Nitro-1,8-(N-propioncarboxylate)succinamidonaphthalene;  
3-Amino-7,4-bis(ethyl-1,3-dioxo)-1,2,3,4-tetrahydrobenzo[i]isoquinoline; and  
2-(2-Hydroxyphenyl)naphthalimide.

✓  
Please cancel claim 8 without prejudice or disclaimer.

✓  
Please add new Claims 14-19 as follows:

#### New Claims

A<sup>3</sup> 14. A method of treating pain in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a composition as defined in claim 1.

15. A method of treating Alzheimer's disease in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a composition as defined in claim 1.